Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.
- 1 May 1991
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 87 (5) , 1724-1731
- https://doi.org/10.1172/jci115190
Abstract
Apolipoprotein C-III is a major protein constituent of triglyceride rich lipoproteins and HDL. It occurs in plasma in three isoforms differing by their sialic acid content. Apo C-III putatively inhibits lipolysis and the apo E mediated hepatic uptake of remnants from triglyceride rich particles. We identified a heterozygous carrier of an apolipoprotein C-III variant by the presence of additional bands after isoelectric focusing (IEF) of VLDL. Structural analysis of the variant protein by HPLC, time-of-flight secondary ion mass spectrometry, and automated gas phase sequencing revealed a lysine to glutamic acid replacement in position 58. The underlying A to G exchange was verified by direct sequencing subsequent to amplification by polymerase chain reaction of exon 4 of the apo C-III gene. Family studies revealed vertical transmission of this defect. The two variant carriers exhibited plasma concentrations of HDL cholesterol and apo A-I above the 95th percentiles of sex matched controls whereas the unaffected father and sister showed normal values. The plasma concentrations of apo C-III in the two variant carriers were decreased by 30-40% compared with those of the two unaffected family members and to random controls. Using two-dimensional immunoelectrophoresis as well as IEF and subsequent scanning densitometry, we found that the low serum concentration of apo C-III was a consequence of diminished concentrations of the variant apo C-III isoproteins in both VLDL (15% of normal) and HDL (25% of normal). Apo C-III(Lys58----Glu) heterozygotes possessed unusual HDL as demonstrated by nondenaturing gradient gel electrophoresis. They consisted mainly of HDL2b and contained a proportion of atypically large particles, enriched in apo E, with a Stokes diameter of 13-18 nm and resembling HDLc. In conclusion, heterozygosity for a structural apo C-III variant--apo C-III(Lys58----Glu)--was identified in two hyperalphalipoproteinemic subjects characterized by the presence of low plasma apo C-III concentrations and atypically large HDL.Keywords
This publication has 62 references indexed in Scilit:
- High-Density Lipoprotein — The Clinical Implications of Recent StudiesNew England Journal of Medicine, 1989
- Simplified Turbidimetric Determination of Apolipoproteins A-I, A-II and B Using a Microtitre Methodcclm, 1988
- Characterization of the specific binding of rat apolipoprotein E-deficient HDL to rat hepatic plasma membranesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1987
- Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.Journal of Clinical Investigation, 1986
- Deficiency of Hepatic Lipase Activity in Post‐heparin Plasma in Familial Hyper‐α‐TriglyceridemiaActa Medica Scandinavica, 1986
- An Economical Assay for HDL Phosphatidyl Cholinecclm, 1983
- Familial Deficiency of Apolipoproteins A-I and C-III and Precocious Coronary-Artery DiseaseNew England Journal of Medicine, 1982
- Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat.Journal of Clinical Investigation, 1980
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoproteinBiochemical and Biophysical Research Communications, 1972